Last updated: August 17, 2026

Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. Current treatments, including riluzole and edaravone, provide limited benefits, underscoring the need for novel therapeutic approaches. Induced pluripotent stem cells (iPSCs) have emerged as a promising tool for understanding ALS pathology and developing potential regenerative therapies.

Pathophysiology of ALS

ALS is characterized by the selective degeneration of upper and lower motor neurons, resulting in muscle atrophy and loss of voluntary movement. The disease is linked to genetic mutations, such as those in the SOD1, C9orf72, and TARDBP genes, as well as oxidative stress, excitotoxicity, and neuroinflammation.

iPSCs in ALS Research and Therapy

  1. Disease Modeling: iPSCs reprogrammed from ALS patient fibroblasts can be differentiated into motor neurons, allowing researchers to study disease mechanisms in vitro. These models have provided insights into neuronal dysfunction, protein aggregation, and axonal transport deficits.
  2. Drug Screening: Patient-specific iPSC-derived motor neurons enable high-throughput drug screening for neuroprotective compounds, accelerating the discovery of potential treatments.
  3. Cell-Based Therapy: Transplantation of iPSC-derived neural progenitor cells or astrocytes holds potential for replacing lost cells and providing trophic support to surviving neurons.

Challenges and Future Directions

Key challenges include ensuring the functional integration and survival of transplanted cells, addressing immune rejection, and mitigating the risk of tumorigenicity. Further research is needed to refine differentiation protocols and enhance the safety of iPSC-based therapies.

Conclusion

iPSC technology has revolutionized ALS research and holds promise for developing novel treatments. While challenges remain, ongoing advancements in stem cell biology may pave the way for effective regenerative therapies for ALS in the future.

Scientific case review

Scientific Case Review

Would you like to understand whether current clinical programs, recent research developments, or emerging approaches may be relevant to your individual situation?

Share your question with our scientific research team and receive information focused on the areas of current research that may be relevant to your case.

  • Review of the information you provide
  • Relevant research and clinical program information
  • A clear response focused on your situation
What happens next? Send your question, receive a focused scientific review, and get a clear response about research and clinical programs relevant to your situation.
Your scientific review will be prepared by Dr. Helen Melnik, PhD , who has more than 25 years of experience in stem cell research and international clinical programs.

No obligation. Your question will be reviewed confidentially.

Educational and research information only. This service does not constitute medical advice, diagnosis, prescription, or a personalized treatment recommendation.


NBScience

contract research organization

WhatsApp